1. Academic Validation
  2. Discovery of novel harmine derivatives as potent, selective, and brain permeable GSK3β inhibitors with effective In vivo anti-AD activity

Discovery of novel harmine derivatives as potent, selective, and brain permeable GSK3β inhibitors with effective In vivo anti-AD activity

  • Eur J Med Chem. 2026 Feb 5:303:118389. doi: 10.1016/j.ejmech.2025.118389.
Wenjie Liu 1 Limeng Wu 2 Xi Zeng 3 Huanhua Chen 4 Xinyue Ning 5 Xiaoyu Sun 6 Wenqiang Xuan 6 Ying Hao 6 Hongli Jia 7 Zhenshu Li 4 Zonghe Xu 4 Xinyu Li 4 Zihua Xu 8 Wenwu Liu 9 Qingchun Zhao 10 Shuang Hao 11
Affiliations

Affiliations

  • 1 College of Life and Health Sciences, Northeastern University, Shenyang, 110819, PR China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China.
  • 2 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
  • 3 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China; National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, 400038, PR China.
  • 4 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
  • 5 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
  • 6 College of Life and Health Sciences, Northeastern University, Shenyang, 110819, PR China.
  • 7 State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, PR China.
  • 8 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China.
  • 9 Department of Pharmacy, Peking University First Hospital, Beijing, 100034, PR China. Electronic address: sunny961010@163.com.
  • 10 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, 110000, PR China; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, PR China. Electronic address: zhaoqingchun1967@163.com.
  • 11 College of Life and Health Sciences, Northeastern University, Shenyang, 110819, PR China. Electronic address: haoshuang@mail.neu.edu.cn.
Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder with limited therapeutic options. Glycogen synthase kinase 3β (GSK3β), a key enzyme in tau phosphorylation, is a promising therapeutic target for AD. Herein, we employed a structure-based drug design strategy to develop a novel series of harmine derivatives as potent GSK3β inhibitors. Among them, compound 39a bearing an intramolecular hydrogen bond scaffold, showed potent GSK3β inhibition (IC50 = 0.37 nM), meanwhile maintaining remarkable kinase selectivity, including >25000-fold selectivity over dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A), a well-known target of β-carboline derivative harmine. It suppressed tau phosphorylation in Tau (P301L) 293T cells (EC50 = 0.06 ± 0.01 μM) and exhibited favorable blood-brain barrier permeability. Notably, 39a significantly attenuated cognitive deficits and tau hyperphosphorylation pathology in OA-induced C57BL/6J mice and 3 × Tg-AD mouse models, without causing spontaneous locomotor defects at therapeutic doses. Collectively, 39a emerges as a promising GSK3β inhibitor for probing GSK3β's role in AD pathogenesis and guiding anti-AD drug discovery.

Keywords

Alzheimer's disease; Blood-brain barrier permeability; GSK3β; Harmine; Tau phosphorylation; β-Carboline.

Figures
Products